Skip to main content
Equibles
KPRX logo

KPRX · Kiora Pharmaceuticals Inc

Track KPRX — free

Use KPRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KPRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.62 -0.04 (-1.50%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — cleared Aug 7, 2026

The latest filing no longer states the doubt (first flagged May 8, 2026).

View the 10-Q filed Aug 7, 2026
Market Cap
$11.77M
Shares
4.42M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.62 Open$2.67 Day$2.62–2.67 52W close$1.80–2.86 Avg vol 30d18K Short int3K · 0.1% float · 1.0d Short vol81% DataJun 2024–Aug 2026 Filing10-Q · Aug 7

Raw chart and full-history price indicators begin at the captured split on Jun 11, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Poor Quant / Vol High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +2%
above
RSI (14) 52
neutral
MACD trend Positive
52-week position 77%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +22%
trailing
YTD return +33%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +10 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.07% of float · ▼ -23.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
22 holders — mid 3-yr range
Squeeze score 32
low risk · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −403%
Y/Y
Free cash flow $-10.1M
Quant / Vol
risk profile
High
Volatility 59%
annualized · 1-yr
Max drawdown −36%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
77% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +10 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.07% of float · ▼ -23.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
22 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 77% Range high $3
vs 200-day avg +13% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and short-term investments $17.1M full year 2025 —
Net cash used in operating activities $10M full year 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KPRX
Kiora Pharmaceuticals Inc
this stock
$11.77M +33.0% -100.0% — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
22
% held
25.0%
Net QoQ
+766.4K sh
Top holder
PERCEPTIVE ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
2.9K
Days to cover
1.0d
Change
-917 sh
View
Short Volume
Short vol %
81%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$13
As of
May 14, 2026
View
Off-Exchange
Off-exchange %
52.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-10.8M
EPS diluted
$-2.64
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 19, 2026
This year
12
View
Exempt Offerings
Offering
$5.0M
Filed
Apr 21, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 11, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
KPRX -1.5% +2.3% +22.4% +2.3% +33.0%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -2.0% -0.7% +9.0% -0.7% +20.2%
Key facts CIK 1372514 CUSIP 49721T507 13F (30d) 23 filings 21 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)